Helsinn Healthcare vs. Teva Pharmaceuticals on Aloxi® patent for the US market

Lugano, Switzerland, and Woodcliff Lake, N.J., May 2, 2017 – A panel of The United States Court of Appeals for the Federal Circuit yesterday reversed the opinion of the District Court for the District of New Jersey and ruled that certain patent claims covering Aloxi® (palonosetron hydrochloride) injection are not valid and are not infringed by Teva’s generic palonosetron product. Teva will not be able to launch a generic version of Aloxi® until additional steps are taken by the Federal Circuit, the New Jersey Court and the Food & Drug Administration ("FDA") allowing such a launch. This process may take several months, and potentially longer if the Federal Circuit were to grant a petition for review.

Helsinn Group and Eisai Inc. are disappointed with the court’s ruling. Protecting intellectual property is vital to a company’s ability to continue developing medicines that will make a difference in the lives of patients. Helsinn and Eisai maintain their position that the patents protecting Aloxi® are valid and will pursue further legal options to protect and enforce such patents.

END

Helsinn Group media contact:

Paola Bonvicini

Group Head of Communications

+41 91-985-21-21

info-hhc@helsinn.com

 

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China as well as a product presence in about 90 countries globally.

For more information, please visit www.helsinn.com.

  

Eisai Inc. media contact:

Laurie Landau

201-746-2510

Laurie_Landau@eisai.com

About Eisai Inc.

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina.

To learn more about Eisai Inc., please visit us at www.eisai.com/US